The axis / receptor to IGF-1
CJC-1295 and the GH / IGF-1 axis: the CJC-1295 IGF-1 axis, traced
Follow the signal: GHRH receptor to pituitary GH pulse to hepatic IGF-1 swell. This is the pathway every CJC-1295 study is really measuring, and where the ipamorelin pairing is argued.
How CJC-1295 moves through the GH / IGF-1 axis
The CJC-1295 IGF-1 axis is the whole story here: the axis is the only thing the compound acts on, and tracing it explains every number in the literature. CJC-1295 binds the GHRH receptor — a class B G-protein-coupled receptor — on the anterior pituitary's somatotroph cells, activating Gs/cAMP/PKA signaling that drives GH gene transcription and pulsatile release [6]. The released growth hormone reaches the liver, engages the GH receptor, and switches on JAK2/STAT5 signaling that produces IGF-1 [6]. Receptor, pulse, swell — that is the axis.
The human numbers map directly onto each step. Single 30-60 microgram-per-kilogram doses raised IGF-1 1.5- to 3-fold for nine to eleven days, and after multiple doses IGF-1 stayed above baseline as long as 28 days [1]. A separate study put mean GH up about 46 percent and IGF-1 up about 45 percent a week after a single dose [2]. The signal is sustained because the DAC form's albumin binding keeps the analog in circulation for days, providing continuous GHRH-receptor stimulation [6].
The most elegant finding in the axis is that the pulse survives. Despite continuous receptor stimulation, the frequency and magnitude of pulsatile GH secretion were unaltered [2] — the pituitary kept releasing GH in its natural rhythm rather than as a flat output. This matters because episodic GHRH has always been more effective than continuous infusion at generating GH pulses [12], so a long-acting analog that preserves pulsatility is doing something the simple pharmacology would not predict.
CJC-1295 and Ipamorelin: the Two-Receptor Rationale
The case for pairing CJC-1295 and ipamorelin rests on two receptors, not on a controlled trial. CJC-1295 acts on the GHRH receptor; ipamorelin is a selective GH secretagogue acting on the ghrelin/GHS receptor — a different protein entirely. The two-pathway rationale comes from a clean experimental finding: ghrelin and GH secretagogues potentiate GHRH-induced GH release, producing more GH together than either pathway alone [11]. That synergy, and the differential way distinct secretagogues control pulsatile GH secretion in healthy men [14], is the entire mechanistic argument for the combination.
What the literature does not contain is a controlled CJC-1295/ipamorelin trial in healthy adults. The pairing is grounded in receptor biology, which is real, but the dosing protocols circulating online are not derived from published combination studies [1]. We present the rationale as a rationale — a plausible two-receptor synergy supported by secretagogue research — and stop short of implying that a specific combination protocol has been validated, because it has not.
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs act through distinct receptors and synergize, producing GH release greater than either alone [11]. The ipamorelin pairing rests on that two-pathway rationale rather than on controlled CJC-1295/ipamorelin trials.
What is CJC-1295 ipamorelin?
It refers to combining the GHRH analog CJC-1295 with ipamorelin, a selective GH secretagogue acting on the ghrelin/GHS receptor; the two act through different receptors and were studied as a synergistic GH-releasing pair in the broader literature [11].
How much CJC-1295 / ipamorelin should I take?
No combination has an established human dose. The pairing is grounded in the GHRH + GHRP synergy rationale [11], but published controlled dosing data for the CJC-1295/ipamorelin combination in healthy adults do not exist.
What the GH / IGF-1 Findings Describe
It is worth being precise about what the GH / IGF-1 findings describe, because this is the section most likely to be read as a list of benefits. They describe measured biomarker movements in research participants — sustained, dose-dependent elevation of GH and IGF-1 over days [1] — not promised personal results. IGF-1 is the downstream hormone through which GH exerts much of its anabolic signal, and a molecular review maps how IGF-1 mediates skeletal-muscle hypertrophy via PI3K/Akt/mTOR signaling while suppressing atrophy pathways [5]. That pathway is the hypothesized route from axis activation to body composition — hypothesized, because no CJC-1295 trial measured those outcomes.
The axis touches more than muscle. In a specific population, GH-secretagogue treatment in hypogonadal men raised serum IGF-1, an example of secretagogue-class effects on the axis [9]. And GHRH administration enhances slow-wave sleep and nocturnal GH secretion in normal men, linking axis stimulation to sleep architecture [10]. These are findings about the GHRH/GH/IGF-1 system broadly; they are included because they describe the territory CJC-1295 operates in, not because CJC-1295 was the agent tested in each.
What to expect when taking CJC-1295?
In the published human PK studies, the measured outcome was sustained, dose-dependent elevation of GH and IGF-1 over days [1]. These describe biomarker responses in research participants, not promised personal results.
How does CJC-1295 affect IGF-1 levels?
By driving pituitary GH release, CJC-1295 raises hepatic IGF-1; single 30-60 microgram-per-kilogram doses produced 1.5- to 3-fold IGF-1 increases lasting nine to eleven days, with IGF-1 above baseline up to 28 days after multiple doses [1].